Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,085 shares of common stock of Twist Bioscience. The shares were sold at a weighted average price of $46.7098 per share to cover tax withholding obligations tied to vesting Restricted Stock Units, under a mandated “sell to cover” arrangement rather than at his discretion.
After this tax-related transaction, Laponis beneficially owns 128,291 shares of common stock, which include shares acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an automatic sale of 7,205 shares of common stock on February 23, 2026 at an average price of $46.7098 per share. The footnotes state this sale was required to cover tax withholding obligations related to vesting restricted stock units under the company’s equity plans and did not represent a discretionary trade. Following this transaction, she directly owned 863,052 common shares. The filing also lists several employee stock option grants and their vesting terms, which remain outstanding holdings rather than new transactions.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported an open-market sale of 1,465 shares of common stock at an average price of $46.7098 per share on February 23, 2026. According to the filing, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under the company’s equity incentive plans, and the sale was mandated as a “sell to cover” transaction rather than a discretionary trade. After this tax-related sale, she beneficially owns 125,336 shares, which include shares acquired through the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 844 shares of common stock at $46.7098 per share. According to the filing, the shares were sold to cover tax withholding owed on vesting restricted stock units under a mandatory “sell to cover” arrangement, rather than a discretionary trade. After this transaction, Cho directly held 138,682 shares.
TWST Form 144 reports a proposed sale of 7,205 common shares tied to restricted stock vesting on 02/20/2026.
The filing also records prior sales by Emily M. Leproust of $74,138.99 for 2,255 shares on 12/08/2025, $55,462.38 for 1,605 shares on 12/22/2025, and $232,924.08 for 5,001 shares on 02/03/2026.
Dennis H. Cho submitted a Form 144 notice relating to the proposed sale of 844 common shares tied to a restricted stock vesting event on 02/20/2026. The filing also lists recent dispositions during the prior three months: 398 shares on 12/08/2025, 324 shares on 12/22/2025, 1,099 shares on 02/03/2026, and 5,000 shares on 02/11/2026.
Fidelity Brokerage Services LLC filed a Form 144 reporting 2,085 shares of common stock for sale on 02/20/2026 tied to a restricted stock vesting event, listed on NASDAQ. The filing also records recent sales by Adam Laponis of 2,738, 3,000, and 7,000 common shares on 01/09/2026, 01/13/2026, and 02/12/2026 respectively, with dollar amounts shown for each sale.
Form 144 filing reports a proposed sale of 1,465 shares of common stock. The filing lists the sale date as 02/20/2026 and states the securities relate to restricted stock vesting described as compensation. The brokerage listed is Fidelity Brokerage Services LLC on NASDAQ.
The filing also discloses prior open-market sales by Paula Green: 12/08/2025 (877 shares for $28,833.66), 12/22/2025 (273 shares for $9,433.79), and 02/03/2026 (1,194 shares for $55,611.15).
Notice of proposed sale and recent transactions by Patrick Finn. The filing lists a restricted stock vesting event of 02/20/2026 covering 4,294 common shares tied to compensation. It also reports multiple sales by Patrick Finn in Jan–Feb 2026, including 68,967 shares sold on 02/17/2026 for $3,562,415.47.
Twist Bioscience reported insider sales by Robert F. Werner. The filing lists sales of Common Stock on 11/24/2025 (822 shares for $23,599.21), 12/08/2025 (230 shares for $7,561.85), 02/03/2026 (175 shares for $8,150.71), and 02/04/2026 (7,000 shares for $319,532.51).
The filing also lists Restricted Stock Vesting of 1,693 Common shares on 02/23/2026 tied to compensation.